Valbiotis

Valbiotis is a French company that describes itself as an expert in the science of plants ("expert de la science du végétal"). It designs innovative food supplements aimed at cardiometabolic health and general well-being, combining botanical expertise with a research-intensive approach. The company states that its patented formulas are validated by clinical studies and developed through more than ten years of research, and that its products are designed and manufactured in France. Valbiotis was created in 2014 in La Rochelle, France, and Wikidata records the company as being located in Périgny, France. According to its own mission page, it operated for more than ten years as a former biotechnology company, investing in research and development to develop natural solutions capable of acting in a documented way on cardiometabolic imbalances. Its expertise rests on plant science and on identifying synergies of active substances able to act on several physiological mechanisms in a complementary manner. The company markets two complementary ranges. Valbiotis Pro® is presented as the expert range for cardiometabolic health, addressing major factors such as blood glucose, weight, cholesterol and blood pressure. Valbiotis Plus® is dedicated to functional disorders and everyday health, such as fatigue, sleep and stress. Products in the Pro range include formulas targeting cholesterol (a patented formula without red yeast rice, with an effect on LDL cholesterol from six weeks, measured on 340 people), metabolic health (triple action on glycemia, triglycerides and weight management), cardio-circulation (blood pressure, cardiovascular health and circulatory comfort), and liver support (including a formula for significant hepatic fat accumulation and one for established dietary imbalances). The Plus range includes a plant-based Omega-3 rich in EPA/DHA from microalgae. Valbiotis emphasizes a high level of evidence. Its mission page states that its approach relies on 13 proprietary randomized, multicentric, international clinical studies conducted on more than 1,500 subjects, along with 64 congress communications and 16 publications in international scientific journals. The company says its research work is recognized in France and internationally. Its formulas are built on patented active substances developed in-house, such as Totum 63, whose development and patent filing are dated to 2015. Valbiotis positions itself at the intersection of nature and science, targeting both health professionals and consumers. Its products are sold through its own website and priced from around €23.95 to €40.95 depending on the formula. The company presents itself as continuing to push the limits of scientific research to offer innovative supplements that combine scientific excellence, plant expertise and rich ingredients.

Valbiotis was created in 2014 in La Rochelle, France. Wikidata records the company as being located in Périgny, France. From its founding, the company invested in research and development with the aim of developing natural solutions capable of acting in a documented way on cardiometabolic imbalances. Its approach combined plant science with the identification of synergies of active substances able to act on several physiological mechanisms in a complementary manner. A key early milestone came in 2015, when the company developed the active substance Totum 63, carried out its first studies and filed a patent. This illustrates the company's model of developing its own patented active substances through several years of research, while also integrating ingredients selected for benefits demonstrated in the scientific literature. According to its mission page, Valbiotis operated for more than ten years as a former biotechnology company, investing in R&D to build a high level of evidence. The company states that its approach relies on 13 proprietary randomized, multicentric, international clinical studies conducted on more than 1,500 subjects, with 64 congress communications and 16 publications in international scientific journals. It says this research work is recognized in France and internationally. Over time, this scientific approach was expressed through two complementary commercial ranges: Valbiotis Pro®, positioned as the expert range for cardiometabolic health, and Valbiotis Plus®, dedicated to functional disorders and everyday health. The Pro range addresses major cardiometabolic factors such as glycemia, weight, cholesterol and blood pressure, while the Plus range addresses associated functional disorders such as fatigue, sleep and stress, with the aim of preserving health globally and sustainably. The company describes itself as continuing to push the limits of scientific research to offer health professionals and consumers innovative food supplements that combine scientific excellence, plant expertise and rich ingredients. Its products are designed and manufactured in France, and are sold notably through its own website, with formulas priced from around €23.95 to €40.95.

• 2015

  Development of the active substance Totum 63, first studies and patent filing.

• 2014

  Creation of the company in La Rochelle, France.

Expert in plant science offering patented, clinically validated food supplements for cardiometabolic health and well-being, designed and manufactured in France.

• Valbiotis Pro® Cholestérol

  Patented formula without red yeast rice; effect on LDL cholesterol from 6 weeks; efficacy measured on 340 people; from €40.95.

• Valbiotis Pro® Santé Métabolique

  Triple action on glycemia, triglycerides and weight management, offering a preventive approach for better metabolic health; from €40.95.

• Valbiotis Pro® Cardio-circulation

  Complete action on circulation: controlled blood pressure, preserved cardiovascular health and optimal circulatory comfort; from €40.95.

• Valbiotis Pro® Foie - Accumulation importante de graisses hépatiques

  Reinforced support in case of hepatic fat accumulation leading to a liver overloaded with fat; from €40.95.

• Valbiotis Pro® Foie - Déséquilibres alimentaires installés

  Supports the liver against dietary imbalances, digestion, hepatic function and fat metabolism; from €23.95.

• Valbiotis Plus® Oméga-3 Végétal

  Rich in EPA/DHA of plant origin from microalgae.

• 2020-04-21

  VALBIOTIS publishes 2019 annual results[5]VALBIOTIS公布2019年度业绩finanznachrichten.de

  Reported: 2020-04-21

  VALBIOTIS published its 2019 annual results, reporting a net loss of €5.504 million and cash of €8.033 million at year end.

• 2020-02-05

  VALBIOTIS and Nestlé Health Science sign TOTUM-63 partnership[6]VALBIOTIS与雀巢健康科学签署TOTUM-63合作协议finanznachrichten.de

  Reported: 2020-02-05

  VALBIOTIS announced that it had signed a global strategic partnership with Nestlé Health Science to develop and commercialize TOTUM-63. The agreement grants Nestlé Health Science exclusive global commercial rights in the prediabetes and Type 2 Diabetes market and includes payments, royalties, and supply of TOTUM-63.

1. 1Valbiotis - Compléments alimentaires santé et bien-être à base de plantesvalbiotis.com
2. 2Le Laboratoire Valbiotis, mission, science, expertisesvalbiotis.com
3. 3Mission Valbiotis, des compléments alimentaires innovantsvalbiotis.com
4. 4Valbiotis (France)wikidata.org
5. 5VALBIOTIS公布2019年度业绩finanznachrichten.de
6. 6VALBIOTIS与雀巢健康科学签署TOTUM-63合作协议finanznachrichten.de